Cargando…

Clinical outcomes associated with complementary and alternative medicine-related “immunity-boosting” practices in patients with cirrhosis during the COVID-19 pandemic – an observational study

During the coronavirus disease 2019 pandemic, Ayurvedic herbal supplements and homeopathic immune boosters (IBs) were promoted as disease-preventive agents. The present study examined the clinical outcomes among patients with chronic liver disease who presented with complications of portal hypertens...

Descripción completa

Detalles Bibliográficos
Autores principales: Philips, Cyriac Abby, Theruvath, Arif Hussain, Raveendran, Resmi, Ahamed, Rizwan, Rajesh, Sasidharan, Abduljaleel, Jinsha K, Tharakan, Ajit, Augustine, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035553/
https://www.ncbi.nlm.nih.gov/pubmed/36961176
http://dx.doi.org/10.1097/MD.0000000000033365
_version_ 1784911437003489280
author Philips, Cyriac Abby
Theruvath, Arif Hussain
Raveendran, Resmi
Ahamed, Rizwan
Rajesh, Sasidharan
Abduljaleel, Jinsha K
Tharakan, Ajit
Augustine, Philip
author_facet Philips, Cyriac Abby
Theruvath, Arif Hussain
Raveendran, Resmi
Ahamed, Rizwan
Rajesh, Sasidharan
Abduljaleel, Jinsha K
Tharakan, Ajit
Augustine, Philip
author_sort Philips, Cyriac Abby
collection PubMed
description During the coronavirus disease 2019 pandemic, Ayurvedic herbal supplements and homeopathic immune boosters (IBs) were promoted as disease-preventive agents. The present study examined the clinical outcomes among patients with chronic liver disease who presented with complications of portal hypertension or liver dysfunction temporally associated with the use of IBs in the absence of other competing causes. This single-center retrospective observational cohort study included patients with chronic liver disease admitted for the evaluation and management of jaundice, ascites, or hepatic encephalopathy temporally associated with the consumption of IBs and followed up for 180 days. Chemical analysis was performed on the retrieved IBs. From April 2020 to May 2021, 1022 patients with cirrhosis were screened, and 178 (19.8%) were found to have consumed complementary and alternative medicines. Nineteen patients with cirrhosis (10.7%), jaundice, ascites, hepatic encephalopathy, or their combination related to IBs use were included. The patients were predominantly male (89.5%). At admission, 14 (73.75%) patients had jaundice, 9 (47.4%) had ascites, 2 (10.5%) presented with acute kidney injury, and 1 (5.3%) had overt encephalopathy. Eight patients (42.1%) died at the end of the follow up period. Hepatic necrosis and portal-based neutrophilic inflammation were the predominant features of liver biopsies. IB analysis revealed detectable levels of (heavy metals) As (40%), Pb (60%), Hg (60%), and various hepatotoxic phytochemicals. Ayurvedic and Homeopathic supplements sold as IBs potentially cause the worsening of preexisting liver disease. Responsible dissemination of scientifically validated, evidence-based medical health information from regulatory bodies and media may help ameliorate this modifiable liver health burden.
format Online
Article
Text
id pubmed-10035553
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-100355532023-03-24 Clinical outcomes associated with complementary and alternative medicine-related “immunity-boosting” practices in patients with cirrhosis during the COVID-19 pandemic – an observational study Philips, Cyriac Abby Theruvath, Arif Hussain Raveendran, Resmi Ahamed, Rizwan Rajesh, Sasidharan Abduljaleel, Jinsha K Tharakan, Ajit Augustine, Philip Medicine (Baltimore) 4500 During the coronavirus disease 2019 pandemic, Ayurvedic herbal supplements and homeopathic immune boosters (IBs) were promoted as disease-preventive agents. The present study examined the clinical outcomes among patients with chronic liver disease who presented with complications of portal hypertension or liver dysfunction temporally associated with the use of IBs in the absence of other competing causes. This single-center retrospective observational cohort study included patients with chronic liver disease admitted for the evaluation and management of jaundice, ascites, or hepatic encephalopathy temporally associated with the consumption of IBs and followed up for 180 days. Chemical analysis was performed on the retrieved IBs. From April 2020 to May 2021, 1022 patients with cirrhosis were screened, and 178 (19.8%) were found to have consumed complementary and alternative medicines. Nineteen patients with cirrhosis (10.7%), jaundice, ascites, hepatic encephalopathy, or their combination related to IBs use were included. The patients were predominantly male (89.5%). At admission, 14 (73.75%) patients had jaundice, 9 (47.4%) had ascites, 2 (10.5%) presented with acute kidney injury, and 1 (5.3%) had overt encephalopathy. Eight patients (42.1%) died at the end of the follow up period. Hepatic necrosis and portal-based neutrophilic inflammation were the predominant features of liver biopsies. IB analysis revealed detectable levels of (heavy metals) As (40%), Pb (60%), Hg (60%), and various hepatotoxic phytochemicals. Ayurvedic and Homeopathic supplements sold as IBs potentially cause the worsening of preexisting liver disease. Responsible dissemination of scientifically validated, evidence-based medical health information from regulatory bodies and media may help ameliorate this modifiable liver health burden. Lippincott Williams & Wilkins 2023-03-24 /pmc/articles/PMC10035553/ /pubmed/36961176 http://dx.doi.org/10.1097/MD.0000000000033365 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 4500
Philips, Cyriac Abby
Theruvath, Arif Hussain
Raveendran, Resmi
Ahamed, Rizwan
Rajesh, Sasidharan
Abduljaleel, Jinsha K
Tharakan, Ajit
Augustine, Philip
Clinical outcomes associated with complementary and alternative medicine-related “immunity-boosting” practices in patients with cirrhosis during the COVID-19 pandemic – an observational study
title Clinical outcomes associated with complementary and alternative medicine-related “immunity-boosting” practices in patients with cirrhosis during the COVID-19 pandemic – an observational study
title_full Clinical outcomes associated with complementary and alternative medicine-related “immunity-boosting” practices in patients with cirrhosis during the COVID-19 pandemic – an observational study
title_fullStr Clinical outcomes associated with complementary and alternative medicine-related “immunity-boosting” practices in patients with cirrhosis during the COVID-19 pandemic – an observational study
title_full_unstemmed Clinical outcomes associated with complementary and alternative medicine-related “immunity-boosting” practices in patients with cirrhosis during the COVID-19 pandemic – an observational study
title_short Clinical outcomes associated with complementary and alternative medicine-related “immunity-boosting” practices in patients with cirrhosis during the COVID-19 pandemic – an observational study
title_sort clinical outcomes associated with complementary and alternative medicine-related “immunity-boosting” practices in patients with cirrhosis during the covid-19 pandemic – an observational study
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035553/
https://www.ncbi.nlm.nih.gov/pubmed/36961176
http://dx.doi.org/10.1097/MD.0000000000033365
work_keys_str_mv AT philipscyriacabby clinicaloutcomesassociatedwithcomplementaryandalternativemedicinerelatedimmunityboostingpracticesinpatientswithcirrhosisduringthecovid19pandemicanobservationalstudy
AT theruvatharifhussain clinicaloutcomesassociatedwithcomplementaryandalternativemedicinerelatedimmunityboostingpracticesinpatientswithcirrhosisduringthecovid19pandemicanobservationalstudy
AT raveendranresmi clinicaloutcomesassociatedwithcomplementaryandalternativemedicinerelatedimmunityboostingpracticesinpatientswithcirrhosisduringthecovid19pandemicanobservationalstudy
AT ahamedrizwan clinicaloutcomesassociatedwithcomplementaryandalternativemedicinerelatedimmunityboostingpracticesinpatientswithcirrhosisduringthecovid19pandemicanobservationalstudy
AT rajeshsasidharan clinicaloutcomesassociatedwithcomplementaryandalternativemedicinerelatedimmunityboostingpracticesinpatientswithcirrhosisduringthecovid19pandemicanobservationalstudy
AT abduljaleeljinshak clinicaloutcomesassociatedwithcomplementaryandalternativemedicinerelatedimmunityboostingpracticesinpatientswithcirrhosisduringthecovid19pandemicanobservationalstudy
AT tharakanajit clinicaloutcomesassociatedwithcomplementaryandalternativemedicinerelatedimmunityboostingpracticesinpatientswithcirrhosisduringthecovid19pandemicanobservationalstudy
AT augustinephilip clinicaloutcomesassociatedwithcomplementaryandalternativemedicinerelatedimmunityboostingpracticesinpatientswithcirrhosisduringthecovid19pandemicanobservationalstudy